307 related articles for article (PubMed ID: 30450336)
1. Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
Cheng X; Liu X; Liu X; Guo Z; Sun H; Zhang M; Ji Z; Sun W
Front Oncol; 2018; 8():494. PubMed ID: 30450336
[No Abstract] [Full Text] [Related]
2. Serum metabolites as early detection markers of non-muscle invasive bladder cancer in Chinese patients.
Zhao Y; Sun W; Ji Z; Liu X; Qiao Y
Front Oncol; 2023; 13():1061083. PubMed ID: 36937410
[TBL] [Abstract][Full Text] [Related]
3. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
4. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
6. Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study.
Batista R; Vinagre J; Prazeres H; Sampaio C; Peralta P; Conceição P; Sismeiro A; Leão R; Gomes A; Furriel F; Oliveira C; Torres JN; Eufrásio P; Azinhais P; Almeida F; Gonzalez ER; Bidovanets B; Ecke T; Stinjs P; Pascual ÁS; Abdelmalek R; Villafruela A; Beardo-Villar P; Fidalgo N; Öztürk H; Gonzalez-Enguita C; Monzo J; Lopes T; Álvarez-Maestro M; Servan PP; De La Cruz SMP; Perez MPS; Máximo V; Soares P
Front Genet; 2019; 10():1237. PubMed ID: 31921291
[TBL] [Abstract][Full Text] [Related]
7. Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.
Ward DG; Baxter L; Ott S; Gordon NS; Wang J; Patel P; Piechocki K; Silcock L; Sale C; Zeegers MP; Cheng KK; James ND; Bryan RT;
Eur Urol Oncol; 2023 Feb; 6(1):67-75. PubMed ID: 35410825
[TBL] [Abstract][Full Text] [Related]
8. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
9. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
[TBL] [Abstract][Full Text] [Related]
10. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.
Tan G; Wang H; Yuan J; Qin W; Dong X; Wu H; Meng P
Sci Rep; 2017 Apr; 7():46176. PubMed ID: 28382976
[TBL] [Abstract][Full Text] [Related]
11. A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
Huang H; Liu A; Liang Y; Xin Y; Liu J; Hao Y; Huang D; Chen L; Li W; Jiang G; Huang Y; Xu Y; Zhang J; Ma T; Xu D; Gao Y
BMC Med; 2023 Sep; 21(1):357. PubMed ID: 37726806
[TBL] [Abstract][Full Text] [Related]
12. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
13. A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer.
Abdelgawad A; Hashem A; Mosbah A; Eissa LA
PLoS One; 2022; 17(6):e0266371. PubMed ID: 35709298
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
[TBL] [Abstract][Full Text] [Related]
15. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
[TBL] [Abstract][Full Text] [Related]
16. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic biomarkers in non-muscle invasive bladder cancer.
Faiena I; Rosser CJ; Chamie K; Furuya H
World J Urol; 2019 Oct; 37(10):2009-2016. PubMed ID: 30467596
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study.
Karaburun MC; Özkaya MF; Ergüder Bİ; Süer E
J Med Syst; 2023 Mar; 47(1):41. PubMed ID: 36976368
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
20. LC-MS based urine untargeted metabolomic analyses to identify and subdivide urothelial cancer.
Yang M; Liu X; Tang X; Sun W; Ji Z
Front Oncol; 2023; 13():1160965. PubMed ID: 37256175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
